Quantcast

Latest Enbrel Stories

2010-08-03 06:00:00

NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Second-Quarter 2010 Revenues of $17.3 Billion Second-Quarter 2010 Reported Diluted EPS((1)) of $0.31, Adjusted Diluted EPS((2)) of $0.62 Reaffirms 2010( )Financial Guidance and 2012 Financial Targets( ) Strong Quarterly Performance Reflects More Balanced Business Mix and Product Portfolio ($ in millions, except per share amounts) Second-Quarter Year-to-Date --------------...

2010-03-23 07:00:00

WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists view Abbott/Eisai's Humira as the most efficacious therapy for the treatment of moderate to severe psoriasis. Thirty-two percent of surveyed dermatologists selected Humira as the most efficacious, followed by Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade (29 percent). The current sales...

2010-02-22 08:45:00

VIENNA, Va., Feb. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model. The results were published in the scientific peer-reviewed Journal of International Immunopharmacology (online edition) in an article titled "CEL-2000: A Therapeutic Vaccine for Rheumatoid Arthritis Arrests Disease...

2010-02-10 07:00:00

WALTHAM, Mass., Feb. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)--the leading therapy in the psoriasis drug market in 2008--will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States,...

2009-11-11 07:00:00

WALTHAM, Mass., Nov. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira....

2009-10-22 09:53:00

WALTHAM, Mass., Oct. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in...

2009-10-16 12:07:00

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Pfizer (NYSE: PFE), today announced new scientific data about ENBREL being presented at the 2009 American College of Rheumatology (ACR) Scientific Meeting in Philadelphia, Pa., from Oct. 17-21, 2009. These presentations contribute to data generated through 17 years of collective clinical experience. "The clinical data being presented at ACR expand on the breadth of...

2009-08-04 15:59:00

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) announcement regarding the results of a safety review of Tumor Necrosis Factor (TNF) blockers [marketed as Remicade(R) (infliximab), Enbrel(R) (etanercept), Humira(R) (adalimumab), Cimzia(R) (certolizumab pegol) and Simponi(R) (golimumab)]. This safety review was...

2009-04-30 10:49:00

Newly Approved Simponi is Expected to Achieve Strong Uptake in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., April 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA)...

2009-01-28 07:00:00

Golimumab Will Earn Decision Resources' Gold Standard for Rheumatoid Arthritis in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists say that a therapy's effect on reducing the signs and symptoms of rheumatoid arthritis at one year is the attribute that most influences their prescribing decisions...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related